| pubmed-article:16023344 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16023344 | lifeskim:mentions | umls-concept:C0291573 | lld:lifeskim |
| pubmed-article:16023344 | lifeskim:mentions | umls-concept:C0022634 | lld:lifeskim |
| pubmed-article:16023344 | lifeskim:mentions | umls-concept:C0042285 | lld:lifeskim |
| pubmed-article:16023344 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16023344 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:16023344 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:16023344 | pubmed:dateCreated | 2005-8-2 | lld:pubmed |
| pubmed-article:16023344 | pubmed:abstractText | Caspase 3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. The P1 aspartic acid residue is a required element of recognition for this enzyme that was maintained constant along with the adjacent natural valine as the P2 group. The thiobenzylmethylketone warhead on the aspartate was conveniently handled through solid-phase synthesis allowing modification in the P3 region that eventually led to simpler derivatives with increased potency against caspase 3. The key to such an effect is the introduction of hydroxyl group alpha to the P3 carbonyl. | lld:pubmed |
| pubmed-article:16023344 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16023344 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16023344 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16023344 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16023344 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:KINGM OMO | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:XanthoudakisS... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:VaillancourtJ... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:RasperDita... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:RoySophieS | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:NicholsonDona... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:HanYongxinY | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:ZamboniRobert... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:ThornberryNan... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:BaylyChristop... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:GrimmErich... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:IsabelEliseE | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:McKayDaniel... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:GirouxAndréA | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:MellonChristo... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:AspiotisReneé... | lld:pubmed |
| pubmed-article:16023344 | pubmed:author | pubmed-author:BlackCameron... | lld:pubmed |
| pubmed-article:16023344 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16023344 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16023344 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:16023344 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16023344 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16023344 | pubmed:pagination | 3886-90 | lld:pubmed |
| pubmed-article:16023344 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:meshHeading | pubmed-meshheading:16023344... | lld:pubmed |
| pubmed-article:16023344 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16023344 | pubmed:articleTitle | Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors. | lld:pubmed |
| pubmed-article:16023344 | pubmed:affiliation | Merck Frosst Centre for Therapeutic Research, Merck Frosst Canada & Co., P.O. Box 1005, Pointe-Claire-Dorval, Que., Canada H9R 4P8. christophe_mellon@merck.com | lld:pubmed |
| pubmed-article:16023344 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16023344 | lld:chembl |
